AXIM Biotech Enters Clinical Study Agreement with University of …

NEW YORK, Aug. 02, 2017 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that it has entered into a Clinical Study Agreement (CSA) with the University of British Columbia in Canada to begin a clinical trial with its CanChew Plus® cannabidiol (CBD) chewing gum product to treat drug-induced psychosis in adult patients.

The University will work with Health Canada and their own ethics board to design the trial, which will be conducted at the University of British Columbia, Canada, and will demonstrate the efficacy of AXIM’s chewing gum product composed of 50mg CBD to treat drug-related psychosis.

“This is another major milestone for AXIM, as we embark on this new clinical program on patients suffering from drug-related psychosis using innovative delivery mechanisms containing cannabinoids,” said George E. Anastassov,

... read more at: